Poly ICLC - Oncovir

Drug Profile

Poly ICLC - Oncovir

Alternative Names: Hiltonol; P.I.C.L.C.; Poly-ICLC; Polyinosinic polycytidylic acid; polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose; Polyriboinosinic-polyribocytidylic acid

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical University of South Carolina; Oncovir
  • Developer Abramson Cancer Center of the University of Pennsylvania; Augusta University; Icahn School of Medicine at Mount Sinai; immatics biotechnologies GmbH; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; New York University School of Medicine; Oncovir; Quest PharmaTech; University Hospitals of Geneva; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Proto oncogene protein c rel modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer; Flavivirus infections; Orthopoxvirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Ovarian cancer; Solid tumours
  • Phase I/II B cell lymphoma; Colorectal cancer; Glioblastoma; HIV infections
  • Phase I Glioma; Prostate cancer
  • No development reported Anaplastic astrocytoma; Cytomegalovirus infections; Influenza virus infections; Pancreatic cancer; Smallpox

Most Recent Events

  • 10 Jan 2018 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IM) (NCT02834052)
  • 08 Dec 2017 Roswell Park Cancer Institute in collaboration with National Cancer Institute plans a phase I trial in Acute myeloid leukaemia and Myelodysplastic syndromes (Combination therapy) in USA (NCT03358719) (Trial profile 700290998)
  • 07 Dec 2017 Dana-Farber Cancer Institute plans a pilot phase I trial for Follicular lymphoma (Combination therapy, First-line therapy) in USA in December 2017 (NCT03361852)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top